BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25849245)

  • 1. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A.
    Akamatsu S; Hayes CN; Ochi H; Uchida T; Kan H; Murakami E; Abe H; Tsuge M; Miki D; Akiyama R; Hiraga N; Imamura M; Aikata H; Kawaoka T; Kawakami Y; Chayama K
    J Hepatol; 2015 Sep; 63(3):554-63. PubMed ID: 25849245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
    O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
    J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study.
    Grzegorzewska AE; Mostowska A; Świderska MK; Marcinkowski W; Stolarek I; Figlerowicz M; Jagodziński PP
    BMC Infect Dis; 2021 Jan; 21(1):102. PubMed ID: 33482747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.
    Peiffer KH; Sommer L; Susser S; Vermehren J; Herrmann E; Döring M; Dietz J; Perner D; Berkowski C; Zeuzem S; Sarrazin C
    Hepatology; 2016 Jan; 63(1):63-73. PubMed ID: 26406534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
    Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
    Morishita N; Sakamori R; Yamada T; Kai Y; Tahata Y; Urabe A; Yamada R; Kodama T; Hikita H; Doi Y; Tamura S; Hagiwara H; Imai Y; Iio S; Tatsumi T; Takehara T
    PLoS One; 2020; 15(6):e0234811. PubMed ID: 32544182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
    Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
    J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with peginterferon and ribavirin.
    Jardim AC; Yamasaki LH; de Queiróz AT; Bittar C; Pinho JR; Carareto CM; Rahal P; Mello IM
    Infect Genet Evol; 2009 Jul; 9(4):689-98. PubMed ID: 19063998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin.
    Sakr AA; Ahmed AE; Abd El-Maksoud MDE; Gamal A; El-Garem H; Ahmed OM
    Infect Genet Evol; 2020 Dec; 86():104606. PubMed ID: 33127459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness.
    Hayashi K; Katano Y; Ishizu Y; Kuzuya T; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Gastroenterol Hepatol; 2015 Jan; 30(1):178-83. PubMed ID: 24995561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.
    Hiraga N; Abe H; Imamura M; Tsuge M; Takahashi S; Hayes CN; Ochi H; Tateno C; Yoshizato K; Nakamura Y; Kamatani N; Chayama K
    Hepatology; 2011 Sep; 54(3):764-71. PubMed ID: 21618576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
    Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
    World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
    Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
    Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
    Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus.
    Aka PV; Kuniholm MH; Pfeiffer RM; Wang AS; Tang W; Chen S; Astemborski J; Plankey M; Villacres MC; Peters MG; Desai S; Seaberg EC; Edlin BR; Strickler HD; Thomas DL; Prokunina-Olsson L; Sharp GB; O'Brien TR
    J Infect Dis; 2014 Feb; 209(3):350-4. PubMed ID: 23956438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
    Yoshimi S; Imamura M; Murakami E; Hiraga N; Tsuge M; Kawakami Y; Aikata H; Abe H; Hayes CN; Sasaki T; Ochi H; Chayama K
    J Med Virol; 2015 Nov; 87(11):1913-20. PubMed ID: 25954851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.
    Maekawa S; Sakamoto M; Miura M; Kadokura M; Sueki R; Komase K; Shindo H; Komatsu N; Shindo K; Kanayama A; Ohmori T; Amemiya F; Takano S; Yamaguchi T; Nakayama Y; Kitamura T; Inoue T; Okada S; Enomoto N
    Hepatology; 2012 Nov; 56(5):1611-21. PubMed ID: 22577043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
    Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.
    Aissa Larousse J; Trimoulet P; Recordon Pinson P; Tauzin B; Azzouz MM; Ben Mami N; Cheikh I; Triki H; Fleury H
    Virol J; 2015 Jun; 12():84. PubMed ID: 26047611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.